Why Siemens Healthineers Cut Its Sales Forecast and Raised Its Profit Target
Siemens Healthineers shares fell on Friday morning after the medical technology group, majority-owned by Siemens and listed on the DAX, published quarterly results that combined a cut in its full-year sales forecast with a higher profit target. The market focused on the revenue warning, with the stock giving back the gains it had made on Wednesday.
The company now expects comparable revenue growth of 3.5 to 4.0 percent for fiscal 2025/26, which ends in September, after previously guiding one percentage point higher. The downgrade is driven by persistent weakness in the lab diagnostics division, a business Siemens Healthineers has flagged for a possible sale. Currency and portfolio effects are excluded from the figure. Analysts had been expecting full-year growth of about 4.5 percent.
At the same time, the company raised its adjusted earnings per share forecast to 2.35 to 2.45 euros, 15 cents above its previous range, after receiving a refund of US tariffs that had been ruled unlawful. Net profit after taxes jumped by more than a fifth to 676 million euros, largely thanks to that reimbursement.
In the third quarter, comparable sales rose 2.8 percent to 5.76 billion euros, short of analyst expectations. Lab diagnostics declined, the group's largest division, Imaging, grew a sluggish 2.3 percent, and Precision Therapy, which includes the US oncology specialist Varian, expanded 9.2 percent. Analysts still see roughly 18 percent upside in the shares from current levels, although the initial market reaction suggests that recovery is not a given.
A Split Quarter: Diagnostics Drag, One-Off Profit Support, Therapy Momentum
The headline numbers tell two different stories. One is a growth problem concentrated in a business the group is trying to exit. The other is an earnings boost that has little to do with day-to-day operations.
Where the Revenue Cut Comes From: Lab Diagnostics
Management reduced the comparable growth range for fiscal 2025/26 by a full percentage point, to 3.5 to 4.0 percent, and pointed to the lab diagnostics unit. That is the same division Healthineers has earmarked for a potential disposal. Weakness there is therefore not just a quarterly miss; it is a reason the divisional portfolio is being restructured. If the unit is sold, the composition of the group's revenue changes, giving more weight to the imaging and therapy businesses.
Imaging and Precision Therapy Tell a Sharper Story
The third quarter shows why the portfolio shift matters. Imaging, the largest segment, grew only 2.3 percent, which the company itself described as sluggish. Precision Therapy, built around Varian, grew 9.2 percent and was the clear outperformer. The group overall grew 2.8 percent, short of analyst expectations, and the full-year consensus of 4.5 percent now sits above management's reduced 3.5 to 4.0 percent range.
The Profit Upgrade Is a One-Off, Not an Operating Trend
The raised adjusted EPS guidance of 2.35 to 2.45 euros is tied to the refund of US tariffs that were deemed illegal, not to stronger demand or better pricing. That same item lifted net profit by more than 20 percent to 676 million euros. The one-off nature of the boost means investors should not extrapolate it into future years, and it partially masks the softer revenue picture beneath.
Market Reaction and the Analyst View
The share price fell on Friday, reversing Wednesday's upward move, and the stock has been trying to form a base since April. Analysts' reported 18 percent upside rests on the shares regaining momentum; with third-quarter growth short of expectations, the burden of proof is on the underlying business rather than the one-off profit tailwind.
How Investors Should Read the Revised Siemens Healthineers Guidance
For investors in Siemens Healthineers, the quarter separates one-off earnings support from the underlying growth story. Three things matter from here:
- Judge the sales cut in the context of the lab diagnostics sale plan. The comparable growth range was lowered by one percentage point to 3.5 to 4.0 percent, and Q3 growth of 2.8 percent missed analyst expectations. Future disclosures on the division's disposal will reshape the group's growth and margin profile.
- Treat the EPS upgrade as a tariff-refund effect. The adjusted target of 2.35 to 2.45 euros is 15 cents higher than before, while net profit rose more than 20 percent to 676 million euros on the back of the refund. That is non-recurring support, not operational leverage.
- Watch the two segments that set the growth narrative. Imaging expanded just 2.3 percent, while Precision Therapy, including Varian, grew 9.2 percent. A re-rating toward the analysts' 18 percent upside case would require Imaging to reaccelerate and the diagnostics drag to shrink.
Risk & Opportunity Assessment
| Commercial Risk | Medium | Comparable revenue growth guidance was cut to 3.5 to 4.0 percent and Q3 growth of 2.8 percent missed expectations, while the EPS upgrade relies heavily on a one-off US tariff refund. |
| Competitive Risk | Medium | Imaging, the largest division, grew just 2.3 percent and lab diagnostics declined, leaving Precision Therapy with Varian, at 9.2 percent growth, as the only clear positive. |
| Regulatory Risk | Low | A refund of US tariffs deemed unlawful lifted profits, but no new regulatory proceeding is reported and the trade-policy exposure appears resolved for now. |
| Reputation Risk | Low | The mixed message of a lower sales outlook alongside a higher profit target may raise questions about earnings quality, but no governance or product-safety issue is reported. |
| Technology Disruption | Low | The story points to demand and portfolio mix problems in diagnostics rather than technological displacement; therapy innovation via Varian remains a growth driver. |
| Commercial Opportunity | Medium | Precision Therapy grew 9.2 percent and analysts see roughly 18 percent upside from current levels; a successful restructuring of the diagnostics portfolio could refocus the group on faster-growing segments. |
Comments 0